782504-42-1

Basic information

• Product Name: 4-Pyridinemethanol, a-(3-fluorophenyl)-
• CAS NO: 782504-42-1
• Molecular Formula: C12H10FNO
• Molecular Weight: 203.216
• Mol File: 782504-42-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-Pyridinemethanol, a-(3-fluorophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Pyridinemethanol, a-(3-fluorophenyl)-(782504-42-1)
• EPA Substance Registry System: 4-Pyridinemethanol, a-(3-fluorophenyl)-(782504-42-1)

Safety Data

• Hazardous Substances Data: 782504-42-1(Hazardous Substances Data)

Upstream product

• 872-85-5 pyridine-4-carbaldehyde 
• 17318-03-5 bromo(3-fluorophenyl)magnesium 

Downstream Products

• 202126-85-0 4-(3-fluorobenzyl)piperidine 
• 193357-21-0 4-(3-fluorobenzyl)piperidine hydrochloride 
• 782504-56-7 4-[(3-fluorophenyl)methyl]pyridine 

Relevant articles and documents

Convenient, benign and scalable synthesis of 2- and 4-substituted benzylpiperidines

A short, scalable and environmentally benign synthesis of 2- and 4-substituted benzylpiperidines has been developed. The method is based on the temperature-programmed consecutive deoxygenation and heteroaromatic ring saturation of aryl(pyridin-2-yl)- and aryl(pyridin-4-yl)methanols and aryl(pyridin-4-yl)methanones in the presence of Pd/C catalyst. The crucial roles of the temperature, the acidity and the substrate structure in the change of selectivity have been demonstrated by isolation of several substituted aryl(piperidine)methanols. The carbinols and ketones were prepared from commercially available pyridinecarbaldehydes or 4-cyanopyridine and substituted bromobenzenes via organometallic intermediates. Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2004.

NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS

The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, IPF, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.